<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056246</url>
  </required_header>
  <id_info>
    <org_study_id>20200290</org_study_id>
    <nct_id>NCT05056246</nct_id>
  </id_info>
  <brief_title>Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants</brief_title>
  <official_title>A Phase I, Open-label, Randomized, Parallel-arm, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after&#xD;
      single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of AMG 133</measure>
    <time_frame>Up to approximately 17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133</measure>
    <time_frame>Up to approximately 17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 133</measure>
    <time_frame>Up to approximately 17 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 17 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. Any clinically significant clinical laboratory tests, 12-lead electrocardiograms (ECGs) and vital signs will also be recorded as AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Incidence of Anti-AMG 133 Antibodies</measure>
    <time_frame>Up to approximately 17 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Group 1: Japanese participants - AMG 133 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Japanese participants - AMG 133 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Japanese participants - AMG 133 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Caucasian participants - AMG 133 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Caucasian participants - AMG 133 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 133</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Group 1: Japanese participants - AMG 133 low dose</arm_group_label>
    <arm_group_label>Group 2: Japanese participants - AMG 133 medium dose</arm_group_label>
    <arm_group_label>Group 3: Japanese participants - AMG 133 high dose</arm_group_label>
    <arm_group_label>Group 4: Caucasian participants - AMG 133 medium dose</arm_group_label>
    <arm_group_label>Group 5: Caucasian participants - AMG 133 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female participants between 18 and 65 years of age (inclusive) at the&#xD;
             time of Screening (Japanese participants must be first-generation Japanese)&#xD;
&#xD;
          2. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations&#xD;
&#xD;
          3. Body mass index between 18 and 30 kg/m^2 at the time of Screening&#xD;
&#xD;
          4. Females of nonchildbearing potential&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History or evidence, at Screening or Check-in, of clinically significant disorder,&#xD;
             condition, or disease&#xD;
&#xD;
          2. History or current signs or symptoms of cardiovascular disease&#xD;
&#xD;
          3. History or evidence of clinically significant arrhythmia at Screening, including any&#xD;
             clinically significant findings on the ECG taken at Check-in&#xD;
&#xD;
          4. History of hypersensitivity, intolerance, or allergy to any drug compound, food, or&#xD;
             other substance&#xD;
&#xD;
          5. Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus&#xD;
             test at Screening&#xD;
&#xD;
          6. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in&#xD;
&#xD;
          7. Use of tobacco- or nicotine-containing products within 6 months prior to Check-in&#xD;
&#xD;
          8. Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol&#xD;
             use at Screening or Check-in&#xD;
&#xD;
          9. Female participants with a positive pregnancy test at Screening or Check-in&#xD;
&#xD;
         10. Female participants lactating/breastfeeding or who plans to breastfeed during the&#xD;
             study through 90 days after the end of study (EOS) visit&#xD;
&#xD;
         11. Donation of blood from 3 months prior to Check-in, plasma from 2 weeks prior to&#xD;
             Check-in, or platelets from 6 weeks prior to Check-in&#xD;
&#xD;
         12. Unwilling to abide with study restrictions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global (Altasciences)</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 133</keyword>
  <keyword>Japanese participants</keyword>
  <keyword>Caucasian participants</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

